BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma

Carcinogenesis

Volumn 28, Issue 8, 2007, Pages 1740-1744

  Hu, Li Li ^a   Wang, Xiao Xiao ^b   Chen, Xiaochao ^a   Chang, Jianhua ^b,c   Li, Caixia ^a   Zhang, Yan ^a   Yang, Jine ^a   Jiang, Wenqi ^b   Zhuang, Shi Mei ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN;

ADULT; AGE; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; WILD TYPE;

AGE FACTORS; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 34548072747     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm113     Document Type: Article

References (27)

1. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89, 3909-3918.
2. Wang,S.S. et al. (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res., 66, 9771-9780.
3. Chiu,B.C. et al. (2003) An update of the epidemiology of non-Hodgkin's lymphoma. Clin. Lymphoma, 4, 161-168.
4. Lossos,I.S. et al. (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J. Clin. Oncol., 24, 995-1007.
5. Cascorbi,I. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Phamacol. Ther., 112, 457-473.
6. McIlwain,C.C. et al. (2006) Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene, 25, 1639-1648.
7. Bartsch,H. et al. (2007) Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res., 174, 19-36.
8. Allikmets,R. et al. (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58, 5337-5339.
9. Doyle,L.A. et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA, 95 15665-15670.
10. Mizuarai,S. et al. (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 109, 238-246.
11. Robey,R.W. et al. (2007) ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev., 26, 39-57.
12. Maliepaard,M. et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61, 3458-3464.
13. Litman,T. et al. (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell. Sci, 113 (Pt 11), 2011-2021.
14. Volk,E.L. et al. (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 62 5035-5040.
15. Iida,A. et al.) (2002) Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet., 47, 285-310.
16. Zamber,C.P. et al. (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics, 13, 19-28.
17. Honjo,Y. et al. (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol. Ther., 1, 696-702.
18. Backstrom,G. et al. (2003) Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur. J. Pharm. Sci., 18, 359-364.
19. Kobayashi,D. et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphims to protein expression in human placenta. Drug Metab. Dispos., 33, 94-101.
20. Korenaga,Y. et al. (2005) Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int. J. Cancer 117, 431-434.
21. Hahn,N.M. et al. (2006) Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin. Cancer Res., 12, 6094-6099.
22. Turner,JJ. et al. (2005) WHO non-Hodgkin's lymphoma classification by criterion-based report review followed by targeted pathology review: an effective strategy for epidemiology studies. Cancer Epidemiol. Biomarkers Prev., 14, 2213-2219.
23. Imai,Y. et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associatea with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther., 1, 611-616.
24. van Herwaarden,A.E. et al. (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimodazo[4,5-b]pyridine. Cancer Res., 63, 6447-6452.
25. van Herwaardeen,A.E. et al. (2006) The function of breast cancer resistance protein in epithelial barriers, stem cells and ma secretion of drugs and xenotoxins. Trends Pharmacol. Sci., 27, 10-16.
26. van Herwaarden,A.E. et al. (2006) Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis, 27, 123-130.
27. de Jong,F.A. et al. (2004) ABCG2 pharmacogmetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res., 10, 5889-5894.